The U.S. Food and Drug Administration (FDA) has once again declined to approve Replimune’s promising candidate for advanced skin cancer, marking a significant setback for the biotech firm and patients seeking recent treatment alternatives. In a decision delivered on Friday, April 10, 2026, the agency issued a Complete Response Letter (CRL) rejecting the application for RP1, an oncolytic immunotherapy designed to treat unresectable advanced cutaneous melanoma via BioSpace.
This second Replimune FDA rejection underscores a growing tension between innovative biotech trial designs and the rigorous evidentiary standards maintained by federal regulators. The drug, known scientifically as vusolimogene oderparepvec, was proposed for use in combination with Bristol Myers Squibb’s Opdivo to target rare and aggressive skin cancers. The news sent immediate ripples through the financial markets, with Replimune’s stock price plummeting nearly 20% on Friday following the announcement via BioSpace.
As a physician and journalist, I have seen how the gap between clinical promise and regulatory approval can be agonizing for patients. RP1 had generated considerable hope, particularly for those who had already failed standard therapies. However, the FDA’s insistence on more traditional trial data has created a roadblock that the company has yet to overcome.
The Single-Arm Trial Controversy
At the heart of the FDA’s decision is a fundamental disagreement over trial methodology. The agency maintained its original objection to the single-arm trial used by Replimune to support the application for RP1. In a single-arm study, all participants receive the experimental treatment, and their results are compared against historical data or a known baseline rather than a concurrent control group receiving a placebo or standard care.
The FDA explicitly stated in its rejection letter that it “would not recommend” granting approval based on results from a single-arm study, asserting that the data presented was “insufficient to conclude substantial evidence of effectiveness” for patients with unresectable advanced cutaneous melanoma via BioSpace. This has develop into a “hot-button issue” within the biotech community, as companies increasingly seek alternative trial designs to accelerate the delivery of medicines to patients with limited options.
To ensure the second review was impartial, the FDA utilized a different set of review team members than those who handled the initial biologics license application. According to the agency, this change was intended to “maintain objectivity and account for potential bias” via BioSpace. Despite this fresh perspective, the conclusion remained the same: the evidence was not substantial enough for approval.
A Timeline of Regulatory Friction
The road to this second rejection has been fraught with conflict. The FDA first spurned the immunotherapy in July 2025, a decision that sparked months of intense controversy. The rejection was so contentious that 22 researchers involved in the drug’s trials took the unusual step of drafting an open letter urging the FDA to “re-review” its decision via BioSpace.
In an attempt to address the agency’s concerns, Replimune resubmitted its application in October 2025. This resubmission included new analyses focusing on RP1’s mechanism of action and a detailed look at how patients fared compared to those who had received prior approved immunotherapies via BioSpace. However, these additional analyses did not satisfy the FDA’s requirement for a more traditional, comparative trial design.
Clinical Promise vs. Regulatory Requirements
Whereas the FDA remains unconvinced by the trial structure, Replimune continues to stand by the clinical efficacy of the drug. The company pointed to the IGNYTE trial as evidence of the drug’s potential. In this trial, patients with confirmed progression on an anti-PD-1 based regimen who received the combination of RP1 and nivolumab (Opdivo) demonstrated a 34% response rate, with a median duration of 24.8 months via Replimune IR.
Replimune has expressed a strong disagreement with the FDA, arguing that the data set—which was sufficient to earn the drug a breakthrough therapy designation—should be enough to develop this medicine available to advanced cancer patients via Replimune IR. The breakthrough therapy designation is intended to expedite the development and review of drugs that display preliminary clinical evidence of substantial improvement over existing therapies, yet in this case, that designation did not pave a smooth path to final approval.
What This Means for the Future of Oncology
The clash between Replimune and the FDA highlights a broader debate in oncology: how to balance the urgent require for new treatments in rare, lethal cancers with the need for gold-standard evidence. For patients with unresectable advanced cutaneous melanoma, the lack of a control group in the RP1 trials is a technicality. for the FDA, it is a matter of scientific integrity and patient safety.
The use of oncolytic immunotherapies—which use viruses to infect and kill cancer cells while stimulating the immune system to attack the tumor—represents a cutting-edge frontier in medical innovation. When these therapies are combined with checkpoint inhibitors like Opdivo, the goal is to create a synergistic effect that can overcome the cancer’s defenses. The IGNYTE trial’s 34% response rate suggests that for a third of the patients, this combination works where other treatments have failed via Replimune IR.
| Metric/Event | Detail |
|---|---|
| Drug Name | RP1 (vusolimogene oderparepvec) |
| Indication | Unresectable advanced cutaneous melanoma |
| First FDA Rejection | July 2025 |
| Second FDA Rejection | April 10, 2026 |
| Primary Objection | Use of a single-arm trial design |
| IGNYTE Trial Response Rate | 34% (with nivolumab) |
| Median Duration of Response | 24.8 months |
For the biotech industry, this outcome serves as a cautionary tale. Relying on breakthrough therapy designations and single-arm trials may accelerate early development, but it does not guarantee a path to market if the FDA decides that the “substantial evidence” threshold has not been met. The 20% drop in stock price reflects the market’s realization that a more costly and time-consuming randomized controlled trial may be the only way forward via BioSpace.
The next critical checkpoint will be Replimune’s official response to the Complete Response Letter. The company must now decide whether to invest in a new, larger trial with a control arm or to continue challenging the FDA’s interpretation of the existing data. Until then, the path to accessibility for vusolimogene oderparepvec remains blocked.
Do you believe regulatory agencies should be more flexible with trial designs for rare, terminal cancers? Share your thoughts in the comments below or share this article with your network.